Understanding Cortical Asymmetry in Autosomal Dominant Alzheimer’s Disease

Recent research is shedding new light on how the brain changes in the earliest stages of Alzheimer’s disease. A study published in Brain Communications has explored the role of cortical asymmetry—the difference in thickness between the left and right hemispheres of the brain—as a potential marker for tracking the progression of autosomal dominant Alzheimer’s disease (ADAD).

By analyzing structural brain changes, researchers are working to better understand the biological continuum of Alzheimer’s, moving beyond traditional diagnostic markers to identify how the disease physically alters brain architecture long before symptoms become severe.

What is Cortical Asymmetry?

The human brain is characterized by a degree of natural symmetry. The cortical asymmetry index is a metric used by neuroscientists to evaluate the difference in cortical thickness between the brain’s two hemispheres. In healthy individuals, these hemispheres maintain a relatively balanced structure. However, in neurodegenerative conditions, this balance can be disrupted as specific regions of the brain atrophy at different rates.

In the context of Alzheimer’s research, scientists investigate whether shifts in this symmetry can serve as a reliable indicator of disease progression, particularly in individuals carrying genetic mutations that cause the disease to manifest early in life.

Key Findings in ADAD Progression

The research, led by Pérez-Millan et al. (2025), utilized data from the Clinic Barcelona cohort and the Dominantly Inherited Alzheimer Network (DIAN) observational study. By examining 60 baseline T1-weighted MRI scans and longitudinal data from 564 participants, the team sought to map how brain structure changes over time in both asymptomatic and symptomatic mutation carriers.

Core Discoveries

• Diagnostic Potential: The study found that the cortical asymmetry index successfully distinguished both asymptomatic and symptomatic mutation carriers from healthy controls in the primary cohort.
• Disease Tracking: In the DIAN observational study cohort, the index was effective in differentiating symptomatic mutation carriers from healthy control subjects.
• Methodology: Researchers employed Freesurfer software to calculate cortical thickness and used generalized additive models to track the longitudinal evolution of asymmetry, adjusting for variables such as age, sex, and the estimated time until the onset of symptoms.

Why This Matters for Early Detection

Autosomal dominant Alzheimer’s disease is a rare, inherited form of the condition that typically presents at a younger age than sporadic Alzheimer’s. Because the genetic cause is known, these patients provide a unique “window” into the progression of the disease before symptoms appear.

By identifying structural changes like cortical asymmetry, clinicians may eventually be able to better predict when an individual is approaching the symptomatic phase of the disease. This is critical for future clinical trials, as interventions are generally most effective when administered in the earliest possible stages of neurodegeneration.

Frequently Asked Questions

How is cortical thickness measured?

Researchers use advanced neuroimaging techniques, specifically T1-weighted MRI scans. Software, such as Freesurfer, is then used to reconstruct the brain’s surface and calculate the thickness of the cerebral cortex across various regions.

Can this test be used for sporadic Alzheimer’s?

While this specific study focused on autosomal dominant Alzheimer’s disease, the methodology for measuring cortical asymmetry is a broad tool in neuroimaging research. Future studies are needed to determine how these findings may translate to the more common, sporadic form of Alzheimer’s.

What are the next steps for this research?

The goal is to integrate these structural markers with other biological data, such as cerebrospinal fluid analysis and plasma neurofilament light chain levels. Combining imaging data with biomarkers provides a more comprehensive view of the Alzheimer’s disease continuum.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.